Higgins, Eibhlin M

Pasteurella species are facultatively anaerobic Gram-negative coccobacilli residing in the upper respiratory tract of mammals, fowl and domestic animals including cats and dogs. Localized infections with Pasteurella species are common but invasive infections are rare. There is a paucity of data available on risk factors, clinical presentations and outcomes with Pasteurella bloodstream infection. We conducted a retrospective review of patients with Pasteurella bacteremia presenting to our institution. There were 63 presentations (61 patients) with Pasteurella bacteremia. Immunosuppression, malignancy and alcohol misuse were common. Rates of admission to intensive care (n = 18, 29.5%) and death prior to hospital discharge (n = 7, 11.5%) were high.

AbstractBackgroundPre‐exposure prophylaxis with tixagevimab‐cilgavimab (tix‐cil) may be associated with cardiovascular adverse events. Also, in vitro studies have reported a reduced activity of tix‐cil against emerging SARS‐CoV‐2 Omicron subvariants. Our study aimed to report the real‐world outcomes of tix‐cil prophylaxis in orthotopic heart transplant (OHT) recipientsMethodsWe retrospectively studied all OHT recipients who received one dose of tix‐cil (150–150 mg or 300–300 mg) at Mayo Clinic in Arizona, Florida, and Minnesota, between February 5, 2022 and September 8, 2022. We collected data on cardiovascular adverse events and breakthrough COVID‐19 following tix‐cil administration.ResultsOne hundred sixty‐three OHT recipients were included. The majority were male (65.6%), and the median age was 61 years (IQR 48, 69). During the median follow‐up of 164 days (IQR 123, 190), one patient presented an episode of asymptomatic hypertensive urgency that was managed with outpatient antihypertensive treatment optimization. Twenty‐four patients (14.7%) experienced breakthrough COVID‐19 at the median of 63.5 days (IQR 28.3, 101.3) after tix‐cil administration. The majority (70.8%) completed the primary vaccine series and received at least one booster dose (70.8%). Only one patient with breakthrough COVID‐19 required hospitalization. All patients survived.ConclusionsIn this cohort of OHT recipients, no patients developed severe cardiovascular events related to tix‐cil. The high incidence of breakthrough COVID‐19 could be due to the reduced activity of tix‐cil against current circulating SARS‐CoV‐2 Omicron variants. These results emphasize the need for a multimodal prevention strategy against SARS‐CoV‐2 in these high‐risk patients. image